Litcius/Paper detail

Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

Gail Matthews, Sanjay Bhagani, Marc van der Valk, Juergen Rockstroh, Jordan J. Feld, Andri Rauch, Christine Thurnheer, Julie Bruneau, Arthur Kim, Margaret Hellard, David Shaw, Ed Gane, Mark Nelson, Patrick Ingiliz, Tanya Applegate, Jason Grebely, P. Marks, Marianne Martinello, Kathy Petoumenos, Gregory J. Dore, Marc van der Valk, Margaret Hellard, Ed Gane, Andri Rauch, Julie Bruneau, Arthur Kim, Sanjay Bhagani, Gregory J. Dore, Pip Marks, Gail Matthews, Jason Grebely, Kathy Petoumenos, Marianne Martinello, Tanya Applegate, Jordan J. Feld, Jürgen K. Rockstroh, Gail Matthews, Pip Marks, Sophia Amjad, Elise Tu, Kathy Petoumenos, Mahshid Tamaddoni, Marc van der Valk, Margaret Hellard, Ed Gane, Maria Christine Thurnheer, Yvonne Gilleece, Julie Bruneau, Mark Nelson, Chris Fraser, Alberto Moriggia, Thomas A. Lutz, Juhi Moon, Phillip Read, Arthur Y. Kim, Andrew Ustianowski, Christiane Cordes, David Shaw, Sanjay Bhagani, Joe Sasadeusz, Mark Hull, Gregory J. Dore, Jordan J. Feld, Jürgen K. Rockstroh, Dominique L. Braun, Patrick Ingiliz, Jürgen K. Rockstroh, Dominique L. Braun, Patrick Ingiliz

2021Journal of Hepatology49 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineClinical endpointIntention-to-treat analysisSofosbuvirPopulationRandomized controlled trialHepatitis CAdverse effectSurgeryHepatitis C virusGastroenterologyRibavirinImmunologyVirusEnvironmental healthHepatitis C virus researchHIV/AIDS drug development and treatmentHIV-related health complications and treatments
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection | Litcius